ArticleAlzheimer's research & therapy2021
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Effects and Mechanisms of Xanthones in Alzheimer's Disease: A Systematic Review.Neurochemical research · 2023Pooled it
- Effects of preventive interventions on neuroimaging biomarkers in subjects at-risk to develop Alzheimer's disease: A systematic review.Frontiers in aging neuroscience · 2022Pooled it
- Digital Technologies to Prevent Social Isolation and Loneliness in Dementia: A Systematic Review.Journal of Alzheimer's disease : JAD · 2022Pooled it
- Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study.European journal of nuclear medicine and molecular imaging · 2022Trial
- A paradigm of the diagnosis and treatment for the whole process of Alzheimer's disease.Annals of medicine · 2026Review
- The potential of low-field MRI for global dementia care.Nature reviews. Neurology · 2026Review
- Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Article
- Knowledge, awareness, and practice of undergraduate medical students on Alzheimer's disease and dementia in Oman.Journal of education and health promotion · 2026Article
- GLP-1 receptor agonists in neurological diseases: mechanisms and therapeutic prospects from metabolism to neuroprotection.Frontiers in immunology · 2026Review
- The impact of dual-tasking on mnestic performance in normal ageing.Scientific reports · 2025Article
- Development and validation of a combined clinical and MRI-based biomarker model to differentiate mild cognitive impairment from mild Alzheimer's disease.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC.Alzheimer's research & therapy · 2025Review
- [Biomolecules · 2025Article
- ABTrans: A Transformer-based Model for Predicting Interaction between Anti-Aβ Antibodies and Peptides.Interdisciplinary sciences, computational life sciences · 2025Article
- Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Could immunotherapy and regulatory T cells be used therapeutically to slow the progression of Alzheimer's disease?Brain communications · 2025Review
- From Fundamentals to Innovation in Alzheimer's Disease: Molecular Findings and Revolutionary Therapies.International journal of molecular sciences · 2024Review
- Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders.The journal of physiological sciences : JPS · 2024Review
- Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease.ACS pharmacology & translational science · 2024Article
- Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.